semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 15.0-70.0,  Asthma Patient is male or female, at least 15 years of age and no more than 70 years Patient has mild persistent asthma (step 2) of the Guidelines for the Diagnosis and Management of Asthma issued by the National Heart, Lung, and Blood Institute of the National Institutes of Health as defined by a history of symptoms at least once a week but less than daily (step 2) (5) Current asthma treatment includes short-acting inhaled β-agonist alone as needed Patient fulfils all the following signs and symptoms of asthma History of symptoms including, but not limited to dyspnea, wheezing, chest tightness, cough, or sputum production for at least 12 months A forced expiratory volume in one second (FEV1) of at least 80% of the predicted value (pre-bronchodilator) while withholding β-agonist for at least six hours Patient has a diagnosis of asthma as defined by 1) an increase in FEV1 or PEF of ≥12% (absolute value), 20 to 30 minutes after inhaled β-agonist administration, OR 2) a positive methacholine PC20 (provocative concentration causing a 20% fall in FEV1) of 8 mg/ml or lower which was performed within the previous 12 months, OR 3) a fall in FEV1 of at least 15% after an exercise challenge which was performed within the previous 12 months. β-agonist reversibility and the methacholine and exercise challenge tests may be satisfied within the previous 12 months if there is adequate source documentation Patients demonstrate symptoms requiring β-agonist use on ≥2 and ≤6 days of the week for the previous two weeks Patient is able to chew a tablet Patient is judged to be in good, stable physical and mental health (except for his/her asthma) based on the medical history, physical examination, and routine laboratory data, and appears able to successfully complete this trial  none
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Asthma Diagnosis of asthma  Are pregnant Take hormonal medication Have an illness with fever (> 38.0 ˚ C or 100.4 ˚ F) within 24 hours of Visit 1 or between Visits 1 and 2 Are participating in another interventional research trial Have other major chronic illnesses that would interfere with participation Are taking the following medications: leukotriene receptor antagonists, oral steroids, anticoagulants, or insulin Are unable to provide consent
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Asthma • 18-50 years old + years old with prior approval to begin an exercise program from primary care physician within 6 months of enrollment Men and women Asthma Doctor diagnosed asthma Lung function tests must meet certain levels common in asthma patients Active, daily doctor-prescribed asthma controller medication (inhaled corticosteroid) for 2 months or longer at a minimum dose equivalent to fluticasone 88 mcg/day, about two (2) puffs. (you can be on other drugs as long as they are in the same dose range as fluticasone) Poor asthma control: Any one of the following conditions Use of beta-agonist (A bronchodilator medicine that opens the airways by relaxing the muscles around the airways that may tighten during an asthma attack )for asthma symptoms twice/week or more OR Awakening from sleep with asthma symptoms more than once per week OR One or more control problems identified on the Asthma Treatment and Control Questionnaire (ATAQ). Smoking status  • Poor lung function Current participation in a regular aerobic exercise program (formal or at home) Any "yes" to any one of items a-e of question number two of the Stanford Usual Activity Questionnaire Pregnancy Sudden illness that accompanies fever (> 38.00 C or 100.40F) within 24 hours of Visit 2 Participation in another interventional research trial Other major chronic illnesses that would interfere with participation in the study Medication use Chronic oral corticosteroid use Oral corticosteroid use within 4 weeks of study start Anti-coagulants (An anticoagulant is a drug that helps prevent the clotting (coagulation) of blood.), insulin, any investigative drugs within 2 months Drug allergy: • Previous adverse effects from methacholine challenge Non-adherence Inability or unwillingness to provide consent
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Asthma Copd Have not smoked during the last year Have never smoked for as long as a year Have < 0.5 packyear  Persons who used inhaled or oral corticosteroids during >5 years, or within the last 5 years FEV1 <1.2 L A subject is not eligible to enter and participate if he does not agree that we inform his general practicioner about participation in the study and also about any unexpected finding during the study Upper respiratory tract infection (e.g. colds), within 2 months Pregnancy, or the possibility of being pregnant (i.e. women who do not use adequate anticonception as judged by the investigator) Malignancy within the past 5 years (except for squamous or basal cell carcinoma of the skin that has been treated with no evidence of recurrence) Signs or symptoms of any other concomitant disease that, in the eyes of the investigator, can interfere with the study results Known recent substance abuse (drug or alcohol) Claustrophobia
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Asthma Male or female out-patient aged from 18 years to 65 years Clinical diagnosis of moderate persistent asthma for at least 6 months, according to GINA revised version 2006 guidelines Post-bronchodilator forced expiratory volume (FEV1) at least 80% of the predicted Either positive methacholine challenge test (PC20 FEV1< 4mg/ml or PD20 FEV1<0.8 mg) or positive response to the reversibility test in the last year Asthma either not adequately controlled with low-dose (≤500 mcg beclomethasone or equivalent) inhaled corticosteroids (ICS) or controlled by bid inhaled combination of low-dose ICS/long acting beta-2 agonists (LABA) A co-operative attitude and ability to be trained to correctly use the dry powder inhalator and to complete the diary cards Written informed consent obtained  Inability to carry out pulmonary function testing Moderate severe asthma associated with reduced lung function History of near-fatal asthma and/or admission intensive care unit because of asthma or more courses of oral corticosteroids or hospitalization for asthma during the previous year Diagnosis of COPD as defined by the GOLD guidelines Evidence of severe asthma exacerbation or symptomatic infection of the airways in the previous 8 weeks Current smokers or recent (less than one year) ex-smokers, defined as smoking at least 10 pack/years History or current evidence of heart failure, coronary artery disease, myocardial infarction, severe hypertension, or cardiac arrhythmias Diabetes mellitis Percutaneous transluminal coronary angioplasty (PTCA) or coronary artery by-pass graft (CABG) during the previous six months
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Asthma symptomatic asthma  usage of inhaled or oral corticosteroids recent febrile respiratory infection severe, unstable asthma
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Influenza Human Any subject (all ages) presenting with ILI (defined as fever [subjective or documented] and cough or sore throat), and suspected of having influenza Subject (parent, guardian, or authorized legal representative) gives informed consent or assent (child) to the study, and provides signed authorization for use and disclosure of protected health information  Any subject classified as "high risk" for exposure to avian or novel influenza, as determined by a Risk-Assessment Questionnaire Subjects who had prior nasal wash/aspirate or nasopharyngeal wash/aspirate specimens collected for routine health-care purposes within the same suspected influenza infection episode
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 7.0-15.0,  Asthma Age 7 years, inclusive Patient has a history of asthma or asthma-like symptoms on at least 1 occasion, occurring at least 3 months prior to the current episode (may be verbal per patient/caregiver) Patient is presenting to the ED for an acute asthma exacerbation of any type or severity Available for phone call or mail questionnaire in 2 weeks and 3 months Parent able to read English or Spanish Child able to understand spoken English or Spanish Child able to use a computer and mouse or stylus Provider believes the patient is likely to remain in ED for at least one hour Informed consent by parent and assent from child  Child has previously participated in this study Child has a hearing impairment uncompensated for by assistive listening devices Significant mental disorder or cognitive impairment that the parent believes would preclude competent informed assent or game play Child has a baseline motor disorder and the parent is unable to assist using a mouse and keyboard Child has significant medial conditions that have a pulmonary component, in addition to their asthma
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Chronic Obstructive Pulmonary Disease (COPD) Diagnosis of chronic obstructive pulmonary disease (COPD) (moderate-to-severe as classified by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) Guidelines, 2007) and Smoking history of at least 10 pack-years Post-bronchodilator forced expiratory volume in 1 second (FEV1) ≤ 65% and ≥ 30% of the predicted normal value Post-bronchodilator FEV1/FVC (forced vital capacity) < 70%  Patients who have received systemic corticosteroids and/or antibiotics and/or was hospitalized for a COPD exacerbation in the 6 weeks prior to screening or during the run-in period Patients who have had a respiratory tract infection within 6 weeks prior to screening Patients with concomitant pulmonary disease Patients with a history of asthma Patients with diabetes Type I or uncontrolled diabetes Type II Any patient with lung cancer or a history of lung cancer Patients with a history of certain cardiovascular comorbid conditions Other protocol-defined inclusion/ applied to the study
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 2.0-90.0,  Hypersensitivity, Immediate Autoinflammatory Syndromes Physical Urticaria Familial Cold Autoinflammatory Syndromes Affected subjects/guardian must: 1. Be at least 2 years of age and no older than 90 years of age. 2. Have a history of a physical urticaria, which has been evaluated by the patient's healthcare practitioner. 3. Provide copies of pertinent medical history and laboratory studies. 4. Have a health care provider outside of NIH. 5. Be willing to give informed consent. 6. Be willing to donate blood for sample storage to be used for future research. Non-affected relatives/guardian must: 1. Be at least 2 years of age and no older than 90 years of age. 2. Have a relative who is enrolled on this protocol and is known to have documented history of a physical urticaria. 3. Not have a history of physical urticaria. 4. Be willing to give informed consent. 5. Be willing to donate blood for sample storage to be used for future research. Normal volunteers must: 1. Be 18-65 years of age. 2. Be non-atopic (not have a history of allergic rhinitis, asthma, atopic dermatitis) per subject s medical history. 3. Have the ability to give informed consent. 4. Be willing to donate blood for sample storage to be used for future research. 5. Not have a history of physical urticaria  The following apply to all subjects: 1. Presence of conditions which, in the judgment of the investigator or the referring physician, may put the subject at undue risk, such as acute infection, severe thrombocytopenia (minimum platelet count of 30,000), or significant cardiovascular disease 2. Any condition that in the view of the principal investigator (PI) would make the subject unsuitable for enrollment in this study 3. History of HIV or other known immunodeficiency 4. History or evidence of chronic Hepatitis B and/or C infection 5. Pregnancy
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Brain and Central Nervous System Tumors Biological parents of a child or adolescent patient diagnosed with low grade glioma (LGG) LGG patients participating in 1 of the following clinical trials On active follow up for study SIOP-LGG1 at a Children's Cancer and Leukemia Group center On study SIOP-LGG-2004 Adoptive parents or guardians allowed if they feel they have the knowledge to complete the study questionnaire, provided either or both biological parents are unable to complete the questionnaire Not specified PRIOR Not specified
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 45.0-75.0,  COPD stable stage II and III (GOLD) COPD, diagnosed 2 years ago and up  Heart failure Malignancy Immune suppressed
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 5.0-15.0,  Bronchial Asthma Children aged 5-15 years of either sex seeking treatment with mild exacerbation of asthma in pediatric chest clinic or Pediatric OPD 2. Mild exacerbation will be defined as children presenting with increase in symptoms (cough, wheeze, breathlessness) for less than 7 days duration no chest indrawing no difficulty in speech clinical asthma score (or pulmonary index score-annexure 1) between 6-9  Children with life threatening asthma detected by presence of any of the following severe chest indrawing cyanosis irregular respiration altered sensorium 2. Children with other chronic respiratory conditions like tuberculosis, cystic fibrosis or other acute illness that would complicate current treatment and response for asthma 3. If child has taken salbutamol in last 6 hours or if he is on long acting beta agonists (formoterol or salmeterol) 4. Child not able to perform spirometry 5. Parents refusing to give consent
Patient description: The patient is a 15-year-old boy with asthma diagnosed a year ago. He presents with shortness of breath, chest tightening and cough. According to his mother, he didn't respond to the usual corticosteroid inhaler. He was admitted to the emergency department with diagnosis of severe asthma exacerbation. He is a candidate for general corticosteroid therapy. Spirometry revealed a forced expiratory volume in the first second (FEV1) of 60% of the predicted. His past medical history is non-significant. His family history is significant for asthma in his mother and his uncle. He used to be treated with combination of inhaled corticosteroids and Zafirlukast.

Clinical trial eligibility criteria: eligible ages (years): 12.0-16.0,  Asthma Moderate to severe persistent asthma African American One or more hospitalizations for asthma in the last 12 months  No exclusions will be made due to co-morbid mental health problems (i.e., attention deficit hyperactivity disorder [ADHD], conduct disorder, depression, anxiety disorder), with the exception of thought disorder (i.e. schizophrenia, autism), suicidality, or mental retardation